Here’s a glimpse of Merck’s blueprint for its new South San Francisco research hub. In keeping with the style of the day, the pharma giant will stick with an open layout which architects insist fosters great collaboration. (Staffers are not always so excited.) Merck will take some time to construct these new quarters, but it’s already beefing up in the Bay Area as it builds its local R&D operations in one of the world’s biggest biotech hubs.
Now that Eli Lilly has finally concluded that the three-time failure sola won’t be making it onto the market as a treatment for Alzheimer’s, the company is cutting “hundreds” of sales staffers who had been recruited to make the commercial effort, according to the Indianapolis Business Journal. Solanezumab failed its latest Phase III test, making it one of the most failed drugs in biopharma history.
Alnylam has been on a roller coaster ride this year with ups and downs for its RNAi work. Over the weekend at ASH it laid claim to encouraging data showing that its hemophilia drug fitusiran had eliminated bleeds in more than half the 16 patients in a small study targeting people with inhibitors that spur resistance to currently used therapies. Bloomberg notes the drug is being stayed as a potential competitor to Roche’s emicizumab, now in a pivotal program.
Pfizer and its partners at Avillion say that a late-stage study of Bosulif for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myeloid leukemia proved successful.
Israel’s NeuroDerm $NDRM says it will scrap a Phase III study and end an ongoing late-stage trial and add PK studies as it ends plans to try and gain an approval based on efficacy, changing its goal to comparative bioavailability.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,000+ biopharma pros who read Endpoints News by email every day.Free Subscription